We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byRickey Tasker
Modified about 1 year ago
Breast Cancer Follow-Up and Management after Primary Treatment AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Introduction This clinical practice guideline provides recommendations on the follow-up and management of asymptomatic patients with breast cancer who have completed primary therapy with curative intent. The guideline was originally published in 1997 and updated in 1999 and ASCO convened an Update Committee to review the results of a systematic review to determine whether the guideline recommendations needed to be updated.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Guideline Methodology: Systematic Review A systematic review of the literature was conducted using MEDLINE and the Cochrane Collaboration Library. Date parameters: March 2006 through March 2012 General search terms: breast neoplasms, surveillance, follow-up Designs: RCTs, systematic reviews (with or without meta- analyses), clinical practice guidelines (with systematic reviews) The ASCO Update Committee reviewed evidence from new publications that met the selection criteria.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Modes of Surveillance Covered History, physical examination Patient education Genetic counseling Breast self-examination Mammography Pelvic examination Coordination of care Routine blood tests (CBC, automated chemistry studies) Imaging studies (chest x-rays, bone scan, ultrasound of the liver, computed tomography, FDG-PET scanning, breast MRI) Breast cancer tumor marker testing (CA 15-3, CA 27.29, carcinoembryonic antigen [CEA])
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Recommendations There were no revisions to the ASCO guideline recommendations. The guideline continues to recommend regular clinical evaluation in conjunction with mammography as the foundation upon which breast cancer follow- up should be based.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION History/Physical Exam and Patient Education Health care providers should counsel patients about the symptoms of possible recurrence: Years After Primary TherapyHistory & Physical Exam Occurs: 1, 2, 3 Every 3 to 6 months 4, 5 Every 6 to 12 months 6+ Annually All women should have a careful history and physical examination. Dyspnea Abdominal pain Persistent headaches New lumps Bone pain Chest pain
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION Referral for Genetic Counseling Women at high risk for familial breast cancer syndromes should be referred to genetic counseling. ‡ Criteria for Genetic Counseling Referral ► Ashkenazi Jewish heritage ► History of ovarian cancer at any age in the patient or any first- or second-degree relatives ► Any first degree relative with a history of breast cancer diagnosed before the age of 50 ► Two or more first- or second-degree relatives diagnosed with breast cancer at any age ► Patient or relative with diagnosis of bilateral breast cancer ► History of breast cancer in a male relative ‡ U.S. Preventive Services Task Force, Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility, Annals of Internal Medicine, 2005
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION Breast Self-Examination Counsel all women to perform monthly breast self-examination (BSE) Inform patients that BSE does not replace mammography as a breast cancer surveillance tool
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION Mammography Post-Treatment Mammogram Schedule FirstNo earlier than 6 months after definitive radiation therapy SubsequentEvery 6 to 12 months for surveillance of abnormalities Subsequent (Conditional) Yearly if stability of mammographic findings is achieved after completion of locoregional therapy Post-treatment mammograms should be performed adhering to the following schedule:
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION Pelvic Examination Regular gynecologic follow-up is recommended for all women. Patients who receive tamoxifen therapy are at increased risk for developing endometrial cancer and should be advised to report any vaginal bleeding to their physicians. Longer follow-up intervals may be appropriate for women who have had a total hysterectomy and oophorectomy.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup RECOMMENDATION Coordination of Care Risk of breast cancer recurrence continues through 15 years after primary treatment and beyond. Any physician performing continuity of care for breast cancer survivors should be experienced in: ► Surveillance of patients in cancer ► Breast examination (including irradiated breasts) Follow-up by a PCP seems to lead to the same health outcomes as specialist follow-up, with good patient satisfaction.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Coordination of Care (cont’d) Patients with early stage breast cancer (tumor <5cm and fewer than 4 positive nodes) who desire follow-up exclusively by a PCP may be transferred approximately 1 year post-diagnosis. If care is transferred to a PCP, both the PCP and the patient should be informed of the appropriate follow- up and management strategy. If the patient is receiving adjuvant endocrine therapy, she will need to be re-referred for oncology assessment. <5cm tumor
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Testing that is NOT recommended
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Routine Blood Tests The following blood tests are NOT recommended for breast cancer surveillance: Complete blood cell count (CBC) Automated chemistry studies
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Imaging Studies The following imaging studies are NOT recommended for routine breast cancer surveillance: Chest x-rays Bone scans Ultrasound of the liver Computed tomography FDG-PET scanning Breast MRI
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Breast Cancer Tumor Marker Testing The following tumor markers are NOT recommended for routine surveillance of breast cancer patients after primary therapy* CA 15-3, CA CEA *The ASCO Breast Cancer Tumor Markers Panel has published guideline recommendations for selected tumor markers. (Harris L. et al. Journal of Clinical Oncology, Vol 25, No 33 [November 20], 2007: pp )
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Summary RECOMMENDED MODES OF BREAST CANCER SURVEILLANCE History/Physical ExamEvery 3 to 6 months for the first 3 years after primary therapy; every 6 to 12 months for years 4 and 5, then annually. Patient EducationCounsel patients about the symptoms of recurrence including new lumps, bone pain, chest pain, abdominal pain, dyspnea or persistent headaches. Referral for Genetic Counseling Criteria to recommend referral include Ashkenazi Jewish heritage; history of ovarian cancer in patient or any first- or second-degree relative; any first degree relative with a history of breast cancer diagnosed before age 50; two or more first- or second-degree relatives diagnosed with breast cancer; patient or relative with diagnosis of bilateral breast cancer; or, history of breast cancer in a male relative. Breast Self-ExamAll women should be counseled to perform monthly breast self-examination. MammographyFirst post-treatment mammogram 1 year after the initial mammogram that leads to diagnosis, but no earlier than 6 months after definitive radiation therapy. Subsequent mammograms should be obtained as indicated for surveillance of abnormalities. Pelvic ExaminationRegular gynecologic follow-up is recommended for all women. Patients who receive tamoxifen should be advised to report any vaginal bleeding to their physicians. Coordination of CareContinuity of care for breast cancer patients is encouraged and should be performed by a physician experienced in the surveillance of cancer patients and in breast examination, including the examination of irradiated breasts. If follow-up is transferred to a PCP, the PCP and the patient should be informed of the long-term options regarding adjuvant hormonal therapy for the particular patient. This may necessitate re-referral for oncology assessment at an interval consistent with guidelines for adjuvant hormonal therapy. BREAST CANCER SURVEILLANCE TESTING - NOT RECOMMENDED Routine blood testsCBCs and liver function tests are not recommended Imaging StudiesChest x-ray, bone scans, liver ultrasound, CT scans, FDG-PET scans, and breast MRI are not recommended Tumor markersCA 15-3, CA and CEA are not recommended.
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Conclusions and Future Research No new evidence was compelling enough to warrant revisions to any of the guideline recommendations. The Update Committee will continue to monitor the literature for new evidence that may warrant revisiting the recommendations. Further research is needed to: determine the comparative effectiveness of different modes of breast cancer surveillance determine the ideal frequency and duration of follow-up establish the clinical utility of tumor marker testing for the follow-up and management of breast cancer evaluate the effectiveness of different models of survivorship care and identify subsets of patients who would benefit from particular models of care
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Patient-Clinician Communication The Update Committee encourages health care providers to have an open dialogue with patient, as part of a comprehensive treatment planning process –ASCO Cancer Treatment Plans and Summary templates are available at At a minimum, the discussion should include: –consideration of scientific evidence –weighing individual risks with potential harms and benefits –patient preferences
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Panel Members NameAffiliation Nancy E. Davidson, MD Co-Chair University of Pittsburgh Cancer Institute and UPMC Cancer Centerr,Pittsburgh, PA James L. Khatcheressian, MD Co-Chair Virginia Cancer Institute, Richmond, VA Elissa Bantug, MHS Johns Hopkins Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD Laura J. Esserman MD, MBA University of California, San Francisco, Carol Franc Buck Breast Care Center and Helen Diller Family Comprehensive Cancer Center. San Francisco, CA Eva Grunfeld, MD, DPhil University of Toronto; Ontario Institute for Cancer Research, Toronto, ON Francine Halberg, MD Marin Cancer Institute, Greenbrae, CA Alexander Hantel, MD Edward Hospital Cancer Centers, Naperville, IL N. Lynn Henry, MD, PhD University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Hyman B. Muss, MD University of North Carolina/Lineberger Comprehensive Cancer Center, Chapel Hill, NC Thomas J. Smith, MD Johns Hopkins Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD Victor G. Vogel, MD Geisinger Medical Center, Danville, PA Antonio C. Wolff, MD Johns Hopkins Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Additional ASCO Resources The guideline updates, this slide set, follow-up planning and management aids, and additional tools are available at:
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup Patient Resources Resources on this topic are available for patients: o ASCO’s website for patients: o American Cancer Society :
©American Society of Clinical Oncology 2012.www.asco.org/guidelines/breastfollowup ASCO Guidelines This resource is a practice tool for physicians based on an ASCO® practice guideline. The practice guideline and this presentation are not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. This presentation does not recommend any particular product or course of medical treatment. Use of the practice guideline and this resource is voluntary. The full practice guideline and additional information are available at Copyright © 2012 by American Society of Clinical Oncology®. All rights reserved.
Screening and Detection in Cancer Survivors Jose W. Avitia, MD Oncology/Hematology.
American Society of Clinical Oncology Endorsement of the Cancer Care Ontario (CCO) Practice Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment.
FOLLOW-UP CARE, SURVEILLANCE PROTOCOL, AND SECONDARY PREVENTION MEASURES FOR SURVIVORS OF COLORECTAL CANCER Clinical Practice Guideline Endorsement
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
©American Society of Clinical Oncology All rights reserved. Adjuvant.
Hereditary Factors in Breast Cancer Jessica Ray, MS, CGC Genetic Counselor.
Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.
Tumor markers Eleni Galani Medical Oncologist. Tumor markers Tumor markers are usually proteins which are produced from cancer cells or as response.
©American Society of Clinical Oncology All rights reserved. Extended RAS Gene Mutation Testing in Metastatic.
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.
Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.
Shiva Sharma SHO to Professor Redmond. Introduction Increased risk groups Consideration of genetic testing Management of patients with mutation.
Mary S. McCabe Survivorship Care Planning. National Directions Focus on recurrence Increasing expectations by patients and families Identification of.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery Associate Chair for Academic Affairs and Research University of Maryland School of Medicine.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Adjuvant Endocrine Therapy for Women with Hormone Receptor- Positive Breast Cancer Clinical Practice Guideline Update.
BREAST CANCER SCREENING Anoop Agrawal, M.D.. NEW USPSTF BREAST SCREENING GUIDELINES Published by US Preventative Screening Task Force in November 2009.
299. Breast Cancer Screening Paul Jones, PGY2 Resident Rounds 25 July 2012.
Survivorship Essentials for Practice Administrators Christina Bach, MBE, MSW, LCSW, OSW-C Carolyn Vachani, MSN, RN, AOCN.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Session Fertility and Pregnancy FL-BBM Specific questions Risk of premature ovarian failure Ability to become pregnant Safety of pregnancy.
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
©American Society of Clinical Oncology All rights reserved. Reprinted.
STRONACH REGIONAL CANCER CENTRE AT SOUTHLAKE CENTRE RÉGIONAL DE CANCÉROLOGIE STRONACH À SOUTHLAKE Follow-up care for Breast Cancer Survivors: Surveillance.
Breast Cancer Risk and Risk Assessment Models Jessica Ray, MS, CGC Cancer Genetic Counselor Ambry Genetic Laboratories ¡Vida! Educational.
Breast Cancer 2010 David B. Pearlstone, MD MBA FACS Co-Director, Breast Division John Theurer Cancer Center Chief, Division of Breast Surgery Hackensack.
Decoding the USPSTF By: Dr Vikram Arora Heritage Valley Health System.
©American Society of Clinical Oncology All rights reserved American.
Endometrial Carcinoma Women ’ s Hospital, School of Medicine, Zhejiang university Women ’ s Hospital, School of Medicine, Zhejiang university.
Complexity, Confusion, Uncertainty – Age Based Mammography Screening Richard L. Theriault, D.O. F.A.C.O.I. Professor Department of Breast Medical Oncology.
YOLANDA LAWSON M.D., F.A.C.O.G MADEWELL OBGYN ASSOCIATE ATTENDING BAYLOR UNIVERSITY MEDICAL CENTER Women's Health Screening Guidelines.
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
The Role of Computed Tomography (CT) Screening for Lung Cancer Recommendations from the American College of Chest Physicians and the American Society of.
Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.
CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.
2009. WHO IS A SURVIVOR? AN INDIVIDUAL IS A SURVIVOR FROM THE TIME OF THEIR DIAGNOSIS THROUGH THE BALANCE OF THEIR LIFE.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
March 10, 2014 NURS 330 Human Reproductive Health.
Survivors Teaching Students: Saving Women’s Lives® A program of the Ovarian Cancer National Alliance.
Familial cancer syndromes: Tools that can help connect the dots in primary care Emily Edelman, MS, CGC NCHPEG Cancer in the family: Primary Care Matters.
HW215: Models of Health & Wellness Unit 7: Health and Wellness Models Geo-political Influences.
Population Management Breast Cancer Screening October 2013.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
OVARIAN CANCER New NICE guidelines and the research behind them Journal Club 20/5/11 Natalie Brown and Matthew Parkes.
Screening Tests for Brest & Cervical Cancer Dr. Yeşim YASİN Spring-2014.
April 6, o What is cancer? o Cancer statistics o Cancer prevention and early detection o Cancer disparities o Cancer survivorship o Cancer research.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
© 2017 SlidePlayer.com Inc. All rights reserved.